![Sergey Selifonov](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sergey Selifonov
Keine laufenden Positionen mehr
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Valery Ivanovich Salygin | M | 86 |
Russian Academy of Sciences
| 34 Jahre |
Sergey Karaganov | M | 71 |
Russian Academy of Sciences
| 35 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Gordon Ringold | M | 73 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 16 Jahre |
Alexei Kudrin | M | 63 |
Russian Academy of Sciences
| 5 Jahre |
Russell Howard | M | 74 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 11 Jahre |
Simba Gill | M | 60 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 16 Jahre |
Michael S. Rabson | M | 70 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 9 Jahre |
Dmitry Shashkov | M | 58 |
Russian Academy of Sciences
| 2 Jahre |
Vladimir Mau | M | 64 |
Russian Academy of Sciences
| 3 Jahre |
Grethe Nørskov Rasmussen | M | 62 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 7 Jahre |
Eugene Buff | M | - |
Russian Academy of Sciences
| 4 Jahre |
Andrey Valentinovich Uralskiy | M | 63 |
Russian Academy of Sciences
| 3 Jahre |
Yevgeny Primakov | M | 94 |
Russian Academy of Sciences
| 19 Jahre |
Alexander Medvedev | M | 68 |
Russian Academy of Sciences
| 11 Jahre |
Anatole A. Klyosov | M | 76 |
Russian Academy of Sciences
| 9 Jahre |
Nikolay Pavlovich Laverov | M | 94 |
Russian Academy of Sciences
| 28 Jahre |
Hans Schambye | M | 59 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 4 Jahre |
Tigran Pogosjan | M | 63 |
Russian Academy of Sciences
| 3 Jahre |
Alexander Vasilyevich Maslov | M | 61 |
Russian Academy of Sciences
| 3 Jahre |
Olga Vysotskaya | F | 63 |
Russian Academy of Sciences
| 2 Jahre |
Sean X. Du | M | - |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 8 Jahre |
Yaroslav Kuzminov | M | 67 |
Russian Academy of Sciences
| 4 Jahre |
Victor Alekseevich Saveliev | M | 61 |
Russian Academy of Sciences
| 3 Jahre |
Paul Quinlan | M | 61 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 5 Jahre |
Vladimir Ivanovich Kruglik | M | 66 |
Russian Academy of Sciences
| 4 Jahre |
Alexander Christoph Becker | M | 64 |
Russian Academy of Sciences
| 3 Jahre |
Howard Allan Simon | M | 65 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 2 Jahre |
Willem P. C. Stemmer | M | - |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | - |
John Bedbrook | M | - |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 3 Jahre |
Marci R. C. Greenwood | M | 81 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 10 Jahre |
Lawrence W. Briscoe | M | 79 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 9 Jahre |
Christian Hansen | M | 58 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 1 Jahre |
Torben Nissen | M | 53 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | - |
Natalia Vilyaminovna Borovkova | F | - |
Russian Academy of Sciences
| 4 Jahre |
Alexander Shokhin | M | 72 |
Russian Academy of Sciences
| 5 Jahre |
Vladimir Dmitriev | M | 70 |
Russian Academy of Sciences
| 1 Jahre |
Andrey Kostin | M | 67 |
Russian Academy of Sciences
| 5 Jahre |
Mikhail Mihaylovich Zadornov | M | 61 |
Russian Academy of Sciences
| 3 Jahre |
Evgeny Viktorovich Melnikov | M | 44 |
Russian Academy of Sciences
| 2 Jahre |
Jan Mikkelsen | M | 65 |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 2 Jahre |
Ruchita Sinha | F | - |
Maxygen, Inc.
![]() Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 4 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Russland | 24 | 58,54% |
Vereinigte Staaten | 17 | 41,46% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Sergey Selifonov
- Persönliches Netzwerk